GURU.Markets stock price, segment price, and overall market index valuation
The company's share price RETA
The historical chart of Reata, a biopharmaceutical company, reflected the success of its drug for the rare neurological disease Friedreich's ataxia. Its story culminated in its acquisition by Biogen in 2023.
Share prices of companies in the market segment - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare and severe neurological diseases. We've categorized it as a Pharma: Neurology company. The chart below reflects how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Reata Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare neurological diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Reata shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
RETA - Daily change in the company's share price RETA
Reata Pharmaceuticals' daily price change reflects the high volatility inherent in biotech companies. This metric measures its sensitivity to news about clinical trials of its drugs for rare diseases.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Before its acquisition by Biogen, Reata Pharmaceuticals was a biopharmaceutical company with an approved drug for a rare disease. Its history exemplifies drug development success. The chart below illustrates the volatility of the biotech sector, where a single successful drug can lead to a major deal.
Daily change in the price of a broad market stock, index - GURU.Markets
Reata Pharmaceuticals is a biotech company working on treatments for neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization RETA
Reata Pharmaceuticals' performance is a story of breakthroughs in rare disease treatments. Its 12-month market cap growth reflects the successful FDA approval of its Friedreich's ataxia drug, as well as its recent acquisition by Biogen, which provided fundamental validation of its scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Reata, a biotech company, developed drugs to treat rare diseases. Its acquisition by Biogen was a recognition of its scientific success. Its past performance reflected both the risks of clinical trials and the potential of its innovative drugs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Reata Pharmaceuticals, a biopharmaceutical company that has achieved success in treating rare neurological diseases, exemplifies the triumph of science. Its year-over-year market capitalization reflects the successful approval and launch of its drug, which led to a sharp increase in value regardless of market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization RETA
Reata, a biopharmaceutical company, achieved success with the approval of its drug. Its monthly performance reflected this commercial and regulatory triumph, culminating in the announcement of its acquisition by Biogen, which determined its final price on this chart.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing new therapeutics for the treatment of severe and life-threatening diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its drugs targeting molecular pathways associated with inflammation and oxidative stress.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Reata Pharmaceuticals is a biopharmaceutical company whose value is tied to the success of its developments. The chart below shows that the company's monthly share price fluctuations are not related to overall market movements, but rather reflect investor expectations regarding clinical trial results and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization RETA
Reata Pharmaceuticals, a biopharmaceutical company focused on rare neurological diseases, exhibits high volatility. Weekly stock performance depends on news about the commercial success of its drugs and the results of new clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Reata Pharmaceuticals and the entire rare disease biotech sector are moving in tandem with investor sentiment and regulatory news. These factors are creating general volatility for everyone. The chart will show how the company fares in this risky but promising field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Reata Pharmaceuticals is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that RETA's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
RETA - Market capitalization of the company RETA
Reata's chart is a financial story of a breakthrough in rare disease treatment. Its high market cap reflects the approval and commercial launch of its drug for Friedreich's ataxia. Its performance is a barometer of how successfully the company can bring a blockbuster drug to market and transform the lives of patients with this devastating disease.
RETA - Share of the company's market capitalization RETA within the market segment - Pharma neurology
Reata Pharmaceuticals specializes in developing drugs for rare and serious diseases. Its significant market capitalization in the biotech sector reflects the success of its regulatory-approved drugs. The company's clout exemplifies how a focus on orphan diseases can lead to blockbusters.
Market capitalization of the market segment - Pharma neurology
Reata Pharmaceuticals is a biotech company focused on treating rare neurological diseases. The chart below shows the overall market capitalization of this complex sector. Its dynamics reflect investor hopes for breakthroughs in the treatment of serious diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Reata is a biopharmaceutical company that has achieved success in treating rare neurological diseases. Its market capitalization chart is a story of breakthroughs in orphan diseases. Its performance reflects the enormous value the market places on drugs for patients who previously had no treatment options.
Book value capitalization of the company, segment and market as a whole
RETA - Book value capitalization of the company RETA
For Reata Pharmaceuticals, book value is its capital. The chart below, especially after the approval of its first drug, shows the financial resources available for its commercialization and further research. This is a story of the transition from R&D to sales.
RETA - Share of the company's book capitalization RETA within the market segment - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company focused on treating rare diseases. Its core capital is intellectual property. Its share of physical assets will be minimal, reflecting its focus on research rather than ownership of large manufacturing facilities.
Market segment balance sheet capitalization - Pharma neurology
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Reata, which develops drugs for rare diseases, is moderately capital-intensive. Commercializing its products requires investments in marketing and supply chains, which weighs down its balance sheet compared to R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Reata Pharmaceuticals is a biotech company that has secured approval for a drug to treat the rare genetic disorder Friedreich's ataxia. The company's assets are the patent for this drug. The company's balance sheet represents the value of the first-ever therapy for this devastating disease, offering real hope to patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - RETA
Reata's balance sheet consists of its cash and the patent for the approved drug. Market capitalization is an estimate of the commercial potential of this drug for a rare disease. The MvsBCap_Co chart shows how much the market values a single successful drug over the company's total assets.
Market to book capitalization ratio in a market segment - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company that has achieved success in treating rare neurological diseases. This chart shows how the market views its commercial drug and scientific potential, which led to its acquisition by a larger player.
Market to book capitalization ratio for the market as a whole
Reata Pharmaceuticals focuses on developing drugs for the treatment of rare and severe diseases. The company's market valuation depends almost entirely on clinical trial results and regulatory approvals. This metric serves as a barometer of investor sentiment regarding the future of its key drugs and represents a significant premium for potential success.
Debts of the company, segment and market as a whole
RETA - Company debts RETA
Prior to its acquisition, Reata Pharmaceuticals used capital to commercialize its drugs for rare diseases. This chart would show how the company prepared for commercial launch, which required significant investment. For biotech companies at this stage, raising capital, including debt, is critical.
Market segment debts - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company specializing in drugs for rare diseases. Its success in obtaining approval for a new drug led to its acquisition by Biogen. This chart may reflect the company's financial performance at its peak as an independent entity.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio RETA
Reata Pharmaceuticals is a biopharmaceutical company that has secured approval for its drug to treat a rare genetic disease. This chart shows its financial position during the transition from R&D to commercialization. It reflects how the company manages capital to organize sales and marketing of its first product.
Market segment debt to market segment book capitalization - Pharma neurology
Reata Pharmaceuticals, recently acquired by Biogen, specializes in developing drugs for rare neurological diseases. Financing such developments is very expensive. The chart shows how the company's pre-acquisition debt load compared to the market capitalization and risk profile of the entire biotech sector.
Debt to book value of all companies in the market
Reata Pharmaceuticals (RETA) is a biopharmaceutical company focused on developing drugs for rare and serious diseases. Having an approved product changes its financial profile. This chart shows its total debt load. It allows us to assess how Reata, now that it has revenue, can begin to use its debt for commercialization and further research.
P/E of the company, segment and market as a whole
P/E - RETA
This chart for Reata Pharmaceuticals reflects its valuation following the approval of its drug for a rare genetic disease. The price-to-earnings ratio depends on the drug's successful commercial launch. The company's valuation is a bet that its first product will be commercially successful and fund further development.
P/E of the market segment - Pharma neurology
This industry metric represents the average P/E for biotech companies. For Reata, following the approval of its first drug, this is an important benchmark. Comparing its P/E to the industry average will help understand how investors view the commercial potential of its drug for treating a rare disease.
P/E of the market as a whole
Reata Pharmaceuticals, acquired by Biogen, specializes in developing drugs for rare and severe diseases. Its breakthrough drug, Skyclarys, became the first approved treatment for Friedreich's ataxia. This chart shows the mood in biotech. Reata's story exemplifies how scientific advancement in treating a rare disease can create enormous value regardless of overall market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company RETA
Reata Pharmaceuticals is a biopharmaceutical company focused on developing treatments for severe, rare diseases. This chart reflects analyst expectations for the commercial success of its recently approved drug. It shows whether experts believe the company can achieve significant sales.
%20P%2FE%20RETA&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-RETA&v=1772618071673 "Chart of the company's future (projected) P/E RETA")
Future (projected) P/E of the market segment - Pharma neurology
Reata Pharmaceuticals specializes in developing drugs for rare and serious diseases. This chart shows average expectations for the pharmaceutical sector. RETA's position may indicate the extent to which investors believe in the commercial success of its approved drugs and the potential of its research to create new treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772618071694 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Reata Pharmaceuticals focuses on developing drugs for rare neurological diseases. The company's success depends on regulatory approvals and the commercialization of its drugs. The overall sentiment in this chart influences the sector, but for Reata, FDA decisions are key.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618071709 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit RETA
Reata Pharmaceuticals is a biopharmaceutical company focused on developing treatments for severe and rare diseases. This chart shows the culmination of years of research. Revenue growth will be driven by the success of its recently approved first-in-class treatment for Friedreich's ataxia.
Profit of companies in the market segment - Pharma neurology
Reata Pharmaceuticals specializes in developing drugs for the treatment of rare and severe neurological diseases. Profitability in this sector, as this chart shows, is determined by the ability to solve complex medical problems affecting small groups of patients. RETA's success depends on regulatory approval and proof of efficacy for its innovative molecules.
Overall market profit
Reata Pharmaceuticals, a biopharmaceutical company focused on rare diseases, operates in a field where science is king. Demand for its drugs is unaffected by the economic climate, as illustrated by this chart. The company's success is determined by the results of clinical trials and its ability to secure regulatory approval for marketing.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company RETA
Reata Pharmaceuticals is focused on developing drugs for rare neurological diseases. This chart reflects analysts' forecasts for future profits, which depend on the commercial success of its currently approved drugs and the clinical trial results of its new candidates.
%20profit%20of%20the%20company%20RETA&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-RETA&v=1772618071805 "Graph of future (projected) profit of the company RETA")
Future (predicted) profit of companies in the market segment - Pharma neurology
Reata Pharmaceuticals specializes in developing drugs to treat rare and severe neurological diseases, such as Friedreich's ataxia. The company operates in an area with a high unmet need. This chart shows the revenue forecast for the neurology sector, reflecting the hopes for the development of therapies for previously incurable genetic diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772618071848 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Reata Pharmaceuticals is a biopharmaceutical company specializing in rare diseases. Demand for its drugs is driven by medical needs, not the economy. However, the overall negative market outlook could complicate price and reimbursement negotiations with insurance companies, which become more cost-conscious in difficult times.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618071884 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - RETA
Reata Pharmaceuticals was a biopharmaceutical company focused on developing drugs for rare diseases. Its pre-acquisition valuation on this chart reflected not so much current revenue as the enormous potential of its approved drug and other candidates in its pipeline for markets with unmet medical needs.
P/S market segment - Pharma neurology
Reata Pharmaceuticals focuses on developing drugs to treat rare and severe diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The chart shows the average revenue estimate in the pharmaceutical industry, helping to gauge how highly investors value its scientific approach to orphan diseases.
P/S of the market as a whole
Reata Pharmaceuticals specializes in developing drugs to treat rare and severe diseases, particularly those related to mitochondrial dysfunction and inflammation. Its success depends on regulatory approval. The graph of average market revenue estimates shows that investors are betting on a breakthrough in the treatment of orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company RETA
Reata Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare, life-threatening diseases. The chart shows the market valuation of its developments. It correlates the company's value with the projected future revenues from its innovative drugs targeting key molecular pathways.
%20P%2FS%20RETA&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-RETA&v=1772618072083 "The graph of the company's future (projected) P/S RETA")
Future (projected) P/S of the market segment - Pharma neurology
Reata Pharmaceuticals focuses on developing drugs to treat rare and severe diseases, particularly those related to inflammation and oxidative stress. This chart shows the average estimated future sales for neuroscience and pharmaceutical companies. It provides insight into how the market views the commercial potential of Reata's approved drugs and its scientific developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772618072092 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Reata Pharmaceuticals was a biopharmaceutical company focused on rare diseases. Its value lay in the potential of its drugs. This graph of general revenue expectations was irrelevant. RETA's fate was determined by the clinical trial results and subsequent approval of its key drug.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618072099 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales RETA
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare diseases. After receiving approval for its products, its revenue, shown in this chart, is generated by sales of these products. Growth is a direct indicator of how successfully the company is bringing its drugs to market.
Sales of companies in the market segment - Pharma neurology
Reata Pharmaceuticals, now part of Biogen, focuses on developing drugs for rare and severe neurological diseases. Their breakthrough product is approved for the treatment of Friedreich's ataxia. This chart shows the sector's total revenue, reflecting the high commercial potential and scientific significance of drugs for orphan neurological diseases.
Overall market sales
Reata Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare neurological diseases. Its success depends on regulatory approval and the commercialization of its products. The overall economic situation, shown in this chart, impacts healthcare system funding and its ability to pay for innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company RETA
Reata Pharmaceuticals, now part of Biogen, specializes in developing drugs for the treatment of severe neurological diseases. Its key product is designed to treat Friedreich's ataxia. This chart reflects the expected commercial success of this drug for this rare but debilitating disease.
%20sales%20of%20the%20company%20RETA&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-RETA&v=1772618072292 "Schedule of future (projected) sales of the company RETA")
Future (projected) sales of companies in the market segment - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of rare and severe neurological diseases. The chart shows forecasts for the neurological pharmaceutical sector. The approval and successful launch of its drugs for rare diseases are key factors for the company's future.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772618072304 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Reata Pharmaceuticals focuses on developing drugs for rare and severe diseases. Its success depends entirely on clinical trial results and regulatory approval. This graph, reflecting overall market sentiment, influences investor willingness to invest in biotech companies with high risk but potentially high rewards if successful.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618072316 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality RETA
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare, life-threatening diseases. Profitability depends on regulatory approval and successful market launches. This chart shows the company's financial path from expensive research to commercialization.
Market segment marginality - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare and serious diseases. This chart shows the average profitability in the pharmaceutical industry. The success of its drugs for rare neurological and renal diseases allows the company to occupy a unique niche and achieve very high profitability.
Market marginality as a whole
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare and serious diseases. Its success depends on clinical trial results and regulatory approval. This total return chart vividly illustrates the high-risk, high-reward nature of biotechnology compared to the market average.
Employees in the company, segment and market as a whole
Number of employees in the company RETA
Reata Pharmaceuticals specializes in developing treatments for rare and serious diseases. This chart shows the size of its team after receiving approval for its first drug. The growth reflects its transition from a purely research-based company to a commercial organization with an in-house sales force.
Share of the company's employees RETA within the market segment - Pharma neurology
Reata Pharmaceuticals achieved success by receiving approval for the first-ever drug to treat the rare genetic disorder Friedreich's ataxia. This triumph is the result of years of work by its team. This graph reflects the scale of this focused scientific team, which was able to bring a drug to market for patients who previously had no treatment options.
Number of employees in the market segment - Pharma neurology
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drugs for rare and serious diseases. The growth of its clinical and commercial teams, as shown in the chart, is driven by regulatory approvals and the launch of its first products. This expansion is a key step in moving to the commercial stage.
Number of employees in the market as a whole
Reata Pharmaceuticals was acquired by Biogen after receiving approval for its drug to treat a rare genetic disease. This chart clearly illustrates the biotech company's transformation. The growth in staff reflects the transition from the R&D phase to the creation of a full-fledged commercial team to bring a breakthrough drug to market, making it an acquisition target.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company RETA (RETA)
Reata Pharmaceuticals is a biopharmaceutical company that has achieved success in treating rare neurological diseases. Following drug approval, market capitalization soars, while staff remains small. This chart is a striking example of the colossal market value (based on a drug monopoly) that a single employee can generate at a successful biotech company.
%20of%20the%20company%20RETA%20(RETA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-RETA-RETA&v=1772618072423 "Chart of market capitalization per employee (in thousands of dollars) of the company RETA (RETA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Reata Pharmaceuticals, recently acquired by Biogen, focused on developing drugs for rare neurological diseases. Its high valuation was based on the potential of its approved and investigational drugs. This chart shows how the market valued its intellectual property relative to its small development team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772618072443 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Reata Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of severe chronic diseases. The chart shows the valuation after the successful approval of a key drug. It reflects how market value soars when a team's years of research and development lead to the development of a sought-after drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618072458 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company RETA (RETA)
Reata (acquired by Biogen) is a biotech company that developed and received approval for a drug (Skyclarys) for the rare disease Friedreich's ataxia. This chart shows the potential profitability of this orphan drug, which was the primary reason for the acquisition.
%20Chart%20RETA%20(RETA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-RETA-RETA&v=1772618072461 "Company Profit Per Employee (in thousands of dollars) Chart RETA (RETA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Reata Pharmaceuticals is a biotech company focused on developing drugs to treat rare, life-threatening diseases. Its drug for Friedreich's ataxia was recently approved and led to the acquisition by Biogen. This chart reflects the effectiveness of the R&D team and serves as a benchmark for how scientific breakthroughs in rare diseases can create enormous value.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772618072482 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Reata Pharmaceuticals (recently acquired by $BIIB) is a biopharmaceutical company that has successfully treated a rare disease (Friedreich's ataxia) with its drug Skyclarys. This graph (pre-acquisition) would show how effectively the R&D team was able to commercialize their breakthrough drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618072521 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee RETA (RETA)
Reata Pharmaceuticals is a biopharmaceutical company specializing in rare diseases. This chart reflects the commercial success of its approved drugs. Revenue per employee growth demonstrates the company's ability to market and successfully sell drugs for patients with limited treatment options.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-RETA-RETA&v=1772618072538 "Sales chart per company employee RETA (RETA)")
Sales per employee in the market segment - Pharma neurology
Reata (RETA) is a biotech company (acquired by Biogen) that successfully developed and commercialized Skyclarys (a treatment for Friedreich's ataxia). This graph would reflect their transition to the commercial stage. All the value was in R&D, and only after the drug's approval would revenue per employee (sales team) begin to grow.
Sales per employee for the market as a whole
Reata Pharmaceuticals is a biotech company focused on neuroscience. This metric reflects their maturity: the company has both R&D projects and commercial drugs. It measures how effectively their commercial assets fund future research and demonstrates the return on investment from their R&D staff and sales.
Short shares by company, segment and market as a whole
Shares shorted by company RETA (RETA)
Reata (RETA) is a biopharmaceutical company that has achieved success in treating rare neurological diseases (Friedreich's ataxia). This chart shows bearish bets. Could bears doubt the long-term commercial potential of their drug or the success of their other developments?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-RETA-RETA&v=1772618072569 "Short Shares Chart for the Company RETA (RETA)")
Shares shorted by market segment - Pharma neurology
Reata Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare neurological diseases and chronic kidney diseases. This chart shows the overall bearish sentiment in the biotech sector, particularly in neurology and nephrology. The rise in short positions in the sector reflects deep investor skepticism about new developments in these challenging areas.
Shares shorted by the overall market
Reata Pharmaceuticals focused on treating rare neurological diseases. Like most biotechs developing new treatments, its valuation was tied to future potential. This chart, signaling rising market fears, illustrates how risk aversion can hit biotechs hard.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator RETA (RETA)
Reata is a biotech company that has achieved success in treating rare neurological diseases (Friedreich's ataxia). This chart is the "pulse" of its success. The "temperature" of investor interest has peaked and plateaued. This reflects the news of the company's acquisition by the giant Biogen, which paid billions for its FDA-approved drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-RETA-RETA&v=1772618072672 "RSI 14 indicator chart for the company's stock RETA (RETA)")
RSI 14 Market Segment - Pharma neurology
Reata Pharma is a biotech company, a rare disease hunter. Their breakthrough was Skyclarys, the first drug for Friedreich's ataxia (acquired by Biogen). The Pharma Neurology (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: was Reata's acquisition driven by their R&D or by general hype in the sector?
RSI 14 for the overall market
For Reata Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RETA (RETA)
Reata Pharmaceuticals (acquired by Biogen) is a biotech company that secured FDA approval for Skyclarys, the first drug to treat Friedreich's ataxia. This chart shows the average analyst forecast. Their targets were based on an assessment of Skyclarys' market potential and, ultimately, the acquisition price by Biogen.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RETA-RETA&v=1772618072746 "A chart showing analyst consensus forecasts for the expected stock price. RETA (RETA)")
The difference between the consensus estimate and the actual stock price RETA (RETA)
Reata is a "winner" in R&D. The biotech company successfully developed and approved Skyclarys, the *first* drug ever to treat a rare disease (Friedreich's ataxia). This chart shows how far the current share price differs from its "fair" value. It reflects analysts' views on their R&D and the price of their acquisition by Biogen.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RETA-RETA&v=1772618072771 "A chart showing the difference between the consensus forecast and the actual stock price. RETA (RETA)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Reata (RETA) is a biotech company that achieved success with Skyclarys, the first approved drug for the rare neurodegenerative disease Friedreich's ataxia. This chart shows general expectations for the neuroscience sector, reflecting whether experts believe R&D in orphan diseases will be commercially successful.
Analysts' consensus forecast for the overall market share price
Reata Pharmaceuticals (RETA) is a successful biotech company. They developed and commercialized Skyclarys, the first-ever treatment for a rare neurological disorder (Friedreich's ataxia). This chart shows the overall risk appetite. It reflects how much the market values companies that translate complex R&D into commercial success (acquired by Biogen).
AKIMA index of the company, segment and market as a whole
AKiMA Company Index RETA
Reata is a biotech R&D company that has crossed the finish line. After years of R&D (and setbacks), they received FDA approval for their first drug (Skyclarys)—the only treatment for a rare neurological disease (Friedreich's ataxia). This chart is a summary indicator of their commercialization, reflecting their (slow) launch and their (enormous) M&A potential.
AKIMA Market Segment Index - Pharma neurology
Reata (RETA) is a neuroscience pharma company. Their biggest success is Skyclarys, the first approved drug for the rare disease Friedreich's ataxia. This represents breakthrough R&D. This chart compares their composite index to the neuroscience sector average.
The AKIM Index for the overall market
Reata Pharmaceuticals is a biotech company that developed Skyclarys for the treatment of Friedreich's ataxia. It was acquired by Biogen. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this rare disease success story compares to overall economic trends.
